The role of new antibiotics in intra-abdominal infections in the era of multi-resistant bacteria

Download PDF Česká verzia

Authors: V. Adámková
Authors place of work: Ústav lékařské mikrobiologie Lékařské fakulty Univerzity Palackého, Olomouc ; Ústav lékařské biochemie a laboratorní diagnostiky Všeobecné fakultní nemocnice v Praze
Published in the journal: Rozhl. Chir., 2019, roč. 98, č. 4, s. 145-151.
Category: Souhrnné sdělení

Summary

Complicated intra-abdominal infections (cIAI) are a substantial cause of morbidity at intensive care units. cIAI are frequently caused by multidrug-resistant strains of Enterobacteriaceae and Pseudomonas aeruginosa. In 592 cIAI patients from the First Department of Surgery, General University Hospital in Prague, we found an alarming increase in resistance of Escherichia coli to amoxicillin/clavulanic acid, piperacillin/tazobactam and third-generation cephalosporins in 2014–2017 (from 28.7% in 2014 to 37.5% in 2017, from 25% to 32% and from 2.3% to 5.6%, respectively). Ceftolozane/tazobactam and ceftazidime/avibactam are novel cephalosporins available for the treatment of cIAI. Ceftolozane/tazobactam is highly active against multidrug-resistant strains of P. aeruginosa, including carbapenem-resistant isolates. The new non-b-lactam b-lactamase inhibitor avibactam plus ceftazidime is active against carbapenemases-producing strains of Enterobacteriaceae. Both antibiotics are included in the new WSES guidelines for the management of cIAI.

Keywords:

complicated intraabdominal infections – bacterial resistance – ceftolozane/tazobactam – ceftazidime/avibactam

Zdroje

Armstrong C. Updated guideline on diagnosis and treatment of intra-abdominal infections. Am Fam Phys. 2010;82:694–709.
Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adultsand children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:133–64. doi: 10.1086/649554.
Sartelli M, Viale P, Catena F, et al. WSES guidelines for management of intra-abdominal infections. World J Emerg Surg. 2013;8:3. doi: 10.1186/1749-7922-8-3.
Chong YP, Bae IG, Lee SR, et al. Clinical andeconomic consequences of failure of initial antibiotic therapy for patientswith community-onset complicated intra-abdominal infections. PLoS One 2015;10:e0119956. doi: 10.1371/journal.pone.0119956
Sartelli M, Catena F, Ansaloni L, et al. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOWStudy. World J Emerg Surg. 2014;9:37. doi: 10.1186/1749-7922-9-37
Hawser SP, Bouchillon SK, Hoban DJ, et al. In vitro susceptibilities of aerobicand facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005–2007: results from the SMARTstudy. Int J Antimicrob Agents. 2009;34:585–8. doi: 10.1016/j.ijantimicag.2009.07.013.
Huang CC, Chen YS, Toh HS, et al. Impact of revisedCLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: resultsfrom the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002–2010. Int J Antimicrob Agents. 2012;40(Suppl.)S4–S10. doi: 10.1016/S0924-8579(12)70003-1.
Kazmierczak KM, Lob SH, Hoban DJ, et al. Characterization of extended-spectrum-lactamases and antimicrobial resistanceof Klebsiella pneumoniae in intra-abdominal infection isolates in Latin America, 2008–2012. Results of the study for monitoring ntimicrobial resistancetrends. Diagn Microbiol Infect Dis. 2015;82:209–14. doi: 10.1016/j.diagmicrobio.2015.03.025.
Badal R, Lob S, Bouchillon S, et al. Susceptibility of intra-abdominal pathogens in Europe, Africa and Middle East—SMART2010/2011. In: 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Annual Meeting. Basel, Switzerland ESCMID 2012.
Swenson BR, Metzger R, Hedrick TL, et al.Choosing antibiotics for intra-abdominal infections: what do we mean by ‘highrisk’? Surg Infect. (Larchmt) 2009;10:29–39. doi: 10.1089/sur.2007.041.
Adámková V, Vaňková A, Ulrych J, et al. Analýza záchytu kvasinek u pacientů po břišním chirurgickém výkonu. Rozhl Chir. 2017;96:426−32.
Wang X, Zhang F, Zhao C, et al. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother. 2014;58:1774–8. doi: 10.1128/AAC.02123-13.
Livermore DM, Mushtag S, Ge Y. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2010;65:1972–4. doi: 10.1093/jac/dkq248
Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60:1462–71. doi:10.1093/cid/civ097.
Miller B, Popejoy MW, Hershberger E, et al. Characteristics and outcomes of complicated intra-abdominal infections involving Pseudomonas aeruginosa from a randomized, double-blind, phase 3 ceftolozane/tazobactam study. Antimicrob Agents Chemother. 2016;60:4387–90. doi: 10.1128/AAC.03074-15.
Zerbaxa™ (ceftolozane sulfate; tazobactam sodium) [package insert]. Lexington, MA: Cubist Pharmaceuticals LLC 2015.
Li H, Estabrook M, Jacoby GA, et al. In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother. 2015;59:1789–93. doi: 10.1128/AAC.04191-14.
Levasseur P, Girard AM, Miossec C, et al. In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamases. Antimicrob Agents Chemother. 2015;59:1931–4. doi: 10.1128/AAC.04218-14.
Mutters NT, Zimmermann S, Kaase M, et al. Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production. Eur J Clin Microbiol Infect Dis. 2015;34:2429–37.
Vasoo S, Cunningham SA, Cole NC, et al. In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing gram-negative bacilli. Antimicrob Agents Chemother. 2015;59:7842–6. doi: 10.1128/AAC.02019-15.
Avycaz™ (avibactam sodium; ceftazidime) [package insert]. Verona, Italy: GlaxoSmithKling 2015
Bassetti M, Carnelutti A, Peghin M. Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections. Expert Review of Anti-infective Therapy 2017;15:55−65. doi: 10.1080/14787210.2017.1251840.
Gürlich R, Adámková V, Ulrych J, et al. Základní principy diagnostiky a léčby sekundární peritonitidy – doporučení odborníků s podporou SIS. Rozhl Chir. 2014;93:334−52.
Sartelli M, Chichom-Mefire A, Labricciosa FM, et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intraabdominal Infections. World Journal of Emergency Surgery 2017;12:29. doi: 10.1186/s13017-017-0141-6.
Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N EnglJ Med. 2015;372:1996–2005. doi: 10.1056/NEJMoa1411162.